Oramed Pharmaceuticl (ORMP) 8.04 $ORMP
Oramed Pharmaceuticals to Present at the BIO International Convention in San Diego
PR Newswire - Mon Jun 23, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chief Executive Officer, Nadav Kidron, will present at the 2014 BIO International Convention. This year's global event for biotechnology will take place on June 23-26 at the San Diego Convention Center in San Diego, California.
Nasdaq stocks posting largest percentage decreases
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Oramed Pharmaceuticals to Present at the American Diabetes Association 74th Scientific Sessions on June 13 - 17, 2014 in San Francisco
PR Newswire - Tue Jun 10, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that three scientific abstracts summarizing studies performed with ORMD-0801, its orally ingestible insulin capsule, were accepted for inclusion at the American Diabetes Association 74th Scientific Sessions, which will take place in San Francisco.
Oramed Pharmaceuticals Added to the Morgan Stanley Capital International (MSCI) MicroCap Index
PR Newswire - Thu May 29, 11:00AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has been added to the Morgan Stanley Capital International (MSCI) MicroCap Index, effective as of market close on May 30, 2014.
A Speculative Biotech Catalyst Trade: ORMP
at The Street - Fri Mar 28, 8:23AM CDT
This beaten-down biotech stock could be ripe for a rebound.
Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes
PR Newswire - Thu Mar 27, 7:45AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM).
5 Stocks With Big Insider Buying
at The Street - Wed Mar 26, 11:43AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals
Marketwire - Thu Mar 20, 8:30AM CDT
LifeSci Advisors, LLC and Oramed Pharmaceuticals (NASDAQ: ORMP)
Oramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide
PR Newswire - Tue Mar 11, 7:30AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government's patent office, has issued the Company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology, including its ORMD-0901 oral exenatide capsule.
Oramed to Present at Upcoming Conferences
PR Newswire - Thu Mar 06, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company will present at the following conferences in March 2014:
Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014
PR Newswire - Mon Mar 03, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
PeopleLinx Achieves 300% Sales Growth in 2013 and Signs Over 40 Top Brands
PR Newswire - Tue Feb 18, 8:03AM CST
PeopleLinx, provider of automated marketing and training solutions for LinkedIn, announced today that the company achieved 300% sales growth in 2013 and signed over 40 new brands. As brands create new sales, marketing and recruitment opportunities through LinkedIn, PeopleLinx has met demand for software that can manage employee training, content sharing and analytics at enterprise scale.
Oramed Pharmaceuticals to Present at the BIO International Convention in San Diego
PR Newswire - Mon Jun 23, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chief Executive Officer, Nadav Kidron, will present at the 2014 BIO International Convention. This year's global event for biotechnology will take place on June 23-26 at the San Diego Convention Center in San Diego, California.
Nasdaq stocks posting largest percentage decreases
AP - Tue Jun 17, 12:27PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Oramed Pharmaceuticals to Present at the American Diabetes Association 74th Scientific Sessions on June 13 - 17, 2014 in San Francisco
PR Newswire - Tue Jun 10, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that three scientific abstracts summarizing studies performed with ORMD-0801, its orally ingestible insulin capsule, were accepted for inclusion at the American Diabetes Association 74th Scientific Sessions, which will take place in San Francisco.
Oramed Pharmaceuticals Added to the Morgan Stanley Capital International (MSCI) MicroCap Index
PR Newswire - Thu May 29, 11:00AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has been added to the Morgan Stanley Capital International (MSCI) MicroCap Index, effective as of market close on May 30, 2014.
A Speculative Biotech Catalyst Trade: ORMP
at The Street - Fri Mar 28, 8:23AM CDT
This beaten-down biotech stock could be ripe for a rebound.
Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes
PR Newswire - Thu Mar 27, 7:45AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the first patient has been enrolled in its U.S. Phase 2a trial for its orally ingestible insulin capsule, ORMD-0801, in the treatment of type 1 diabetes (T1DM).
5 Stocks With Big Insider Buying
at The Street - Wed Mar 26, 11:43AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
at The Street - Tue Mar 25, 1:35PM CDT
Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.
LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals
Marketwire - Thu Mar 20, 8:30AM CDT
LifeSci Advisors, LLC and Oramed Pharmaceuticals (NASDAQ: ORMP)
Oramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide
PR Newswire - Tue Mar 11, 7:30AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government's patent office, has issued the Company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology, including its ORMD-0901 oral exenatide capsule.
Oramed to Present at Upcoming Conferences
PR Newswire - Thu Mar 06, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company will present at the following conferences in March 2014:
Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014
PR Newswire - Mon Mar 03, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
PeopleLinx Achieves 300% Sales Growth in 2013 and Signs Over 40 Top Brands
PR Newswire - Tue Feb 18, 8:03AM CST
PeopleLinx, provider of automated marketing and training solutions for LinkedIn, announced today that the company achieved 300% sales growth in 2013 and signed over 40 new brands. As brands create new sales, marketing and recruitment opportunities through LinkedIn, PeopleLinx has met demand for software that can manage employee training, content sharing and analytics at enterprise scale.
